Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinogen Replacement to Prevent Intracranial Haemorrhage After Thrombolysis in Ischemic Stroke (Pilot RCT)
2024-516731-27-00Phase 3Authorised
- Sponsor
- Azienda USL di Bologna
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Fibrinogen human in ischemic stroke and acute intracranial hemorrhage (ICH) (2 arms), sponsored by Azienda USL di Bologna. Primary endpoints: Rate of intracranial haemorrhage (parenchymal hematoma PH1, PH2 and remote hematomas) and Rate of symptomatic intracranial haemorrhage (sICH) and extracerebral bleedings. Planned start Sep 2024; status: authorised.
02
Drugs
Fibrinogen human
03
Conditions
ischemic strokeacute intracranial hemorrhage (ICH)
Beyond the preview
Go deeper on 2024-516731-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516731-27-00.